Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?

Vanguard Health Care ETF (VHT) is positioned as the cheaper option versus iShares Global Healthcare ETF (IXJ), charging a 0.09% expense ratio vs 0.38% (about $9 vs $38 annually on a $10,000 investment). VHT also offers a slightly higher trailing dividend yield of 1.55% vs 1.44% and broader diversification (417 holdings vs 110), while both funds are heavily concentrated in Eli Lilly, Johnson & Johnson, and AbbVie. Over the past year VHT returned 31.21% vs IXJ’s 23.92%, with similar 5-year max drawdowns (-17.71% vs -18.14%).

Analysis

This is less a healthcare fundamental call than a wrapper-quality trade. The structural edge is on the lower-cost, broader vehicle: over long horizons, fee drag is the only truly certain alpha source here, and it compounds materially when both funds own a similar mega-cap core. If passive healthcare allocations continue to grow, the cheaper vehicle should be the default destination, which creates a slow but persistent AUM and liquidity advantage.

The more interesting second-order effect is that the “global” sleeve does not buy much real diversification; it mainly adds currency, reimbursement, and political-regime risk without enough factor separation to justify the extra basis points. In a strong-dollar or U.S.-leadership tape, that foreign exposure becomes a headwind, while the U.S.-heavy fund benefits from cleaner exposure to domestic pricing power and capital-return names. That makes the relative trade more compelling as a 6-18 month allocation decision than as a days-long event trade.

The contrarian read is that the market may be overestimating how much can be won by moving between these two ETFs in the near term. With the same top holdings dominating both baskets, near-term relative performance will mostly be driven by LLY/ABBV/JNJ beta rather than wrapper choice; the fee differential matters, but it won’t show up overnight. The falsifier is simple: if ex-U.S. healthcare outperforms on sustained USD weakness or a regional policy re-rating, IXJ can close the gap despite its higher fee load.

Key Decisions for Investors

• Core allocation: prefer VHT over IXJ for new healthcare capital on a 6-18 month horizon; the expected edge is small annually but durable, with lower fee drag and broader constituent breadth compounding over time.
• Pair trade: long VHT / short IXJ in roughly equal dollars for a 3-5% relative-return target over 12 months; the thesis fails if foreign healthcare starts to outperform on USD weakness or non-U.S. policy support.
• If forced to express healthcare defensiveness tactically, use VHT rather than IXJ because it keeps exposure closer to U.S. megacap pharma and reduces FX/regulatory noise.
• Watch item: if VHT continues to gather AUM faster than IXJ over the next 1-3 months, treat that as flow confirmation and consider adding to the relative-value position; if not, close the trade and keep the sector exposure unhedged.